Eukaryotic Cell Patents (Class 424/93.21)
  • Patent number: 11116795
    Abstract: The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: September 14, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nicola Mason, Daniel J. Powell, Jr., Mohammed Kazim Panjwani, Jenessa Smith
  • Patent number: 11116798
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: September 14, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • Patent number: 11111286
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: September 7, 2021
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Leonie Alten, Dominik Maurer, Sebastian Bunk, Claudia Wagner, Mathias Ferber
  • Patent number: 11103596
    Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional ?-galactosidase A protein wherein the nucleotide sequence has at least 85% identity to the sequence of SEQ ID NO. 1. Also described is a vector, host cell or transgenic animal comprising the nucleic acid molecule; and a pharmaceutical composition comprising the nucleic acid molecule or the vector. Further, the use of the nucleic acid molecule in a method of treating Fabry disease is described.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 31, 2021
    Assignee: UCL BUSINESS PLC
    Inventors: Amit Nathwani, Deepak Raj
  • Patent number: 11103532
    Abstract: The present invention provides a chimeric protein having the formula: Casp-Ht1-Ht2 wherein Casp is a caspase domain; Ht1 is a first heterodimerization domain; and Ht2 is a second heterodimerization domain and wherein, in the presence of a chemical inducer of dimcrization (CID), an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains. The invention also provides a cell comprising such a protein and its use in adoptive cell therapy.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: August 31, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Ryan Trowbridge, Edward Hodgkin
  • Patent number: 11104881
    Abstract: The present invention relates to the field of stem cells. More specifically, the present invention provides methods and compositions useful for the highly efficient conversion of human stem cells to lineage-specific neurons. In a specific embodiment, a method of inducing differentiation of human stem cells into dopaminergic (DA) neurons comprises the steps of (a) transfecting human stem cells with a lentiviral vector encoding Atoh1, wherein the vector is Dox inducible; and (b) growing the transfected cells in culture in the presence of Dox, Sonic Hedgehog (SHH) and FGF-8b until DA neurons are induced.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: August 31, 2021
    Assignee: The Johns Hopkins University
    Inventors: Mingyao Ying, John Laterra
  • Patent number: 11098319
    Abstract: Methods and compositions are described for producing a glucanase in transgenic plants and then incorporating parts of the transgenic plants in animal feed. The feed glucanase enzyme displays activity across a broad pH range, and tolerance to temperatures that are often encountered during the process of preparing animal feeds. Producing the enzyme in the transgenic plant enhances the thermal stability of the enzyme.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: August 24, 2021
    Assignee: AGRIVIDA, INC.
    Inventors: R. Michael Raab, Oleg Bougri, Xuemei Li
  • Patent number: 11091532
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 17, 2021
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
  • Patent number: 11091780
    Abstract: Described herein are methods and compositions for autocatalytic genome editing and neutralizing autocatalytic genome editing. The autocatalytic genome editing may be based on genomic integration of a construct containing multiple elements or on a trans-complementation approach, in which genetic elements can be propagated separately. The disclosure provides a method for autocatalytic genome editing based on the CRISPR/CAS9 system, and methods of use thereof, in animals, humans, and plants for eliminating pathogens, targeting suppression of crop pests, strategies to combat virus (e.g., HIV) and other diseases (e.g., cancer) caused by retrovirus, as well as to generate homozygous mutations that are transmitted to nearly all offspring.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 17, 2021
    Assignee: The Regents of the University of California
    Inventors: Ethan Bier, Valentino Gantz, Stephen Hedrick
  • Patent number: 11090336
    Abstract: Various TnMUC1-specific chimeric antigen receptors (CARs), nucleic acids encoding the same, and methods of using the same, are provided. Compositions and methods comprising a TnMUC1-specific CAR for treating MUC1-associated cancer in a subject in need thereof are provided.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: August 17, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Avery D. Posey, Carl H. June
  • Patent number: 11084864
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 10, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
  • Patent number: 11078461
    Abstract: The invention provides compositions and methods for the preparation of processed adipose tissue. The invention further provides methods of use of the processed adipose tissue.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: August 3, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Zayna Nahas, Jennifer H. Elisseeff, Iwen Wu
  • Patent number: 11077145
    Abstract: The present invention relates to the method for mass production of mesenchymal stem cell-derived proteins including various growth factors and cytokines, a mesenchymal stem cell conditioned medium containing a large amount of protein and produced by the above production method, cosmetic composition and pharmaceutical composition including the above conditioned medium for skin regeneration, anti-wrinkle, alopecia treatment, prevention of hair loss and promotion of hair growth.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: August 3, 2021
    Assignee: STEMMEDICARE CO., LTD.
    Inventor: Jang Ho Lee
  • Patent number: 11078462
    Abstract: The invention provides methods, compositions and kits for making and using pericyte-like cells or perivascular stromal cells derived from pPS cells.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: August 3, 2021
    Assignee: ReCyte Therapeutics, Inc.
    Inventors: Jiwei Yang, Dana Larocca, Midori Greenwood-Goodwin
  • Patent number: 11077207
    Abstract: The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: August 3, 2021
    Assignee: CURAMYS INC.
    Inventors: Jung-Joon Sung, Seung-Yong Seong, Hee-Woo Lee, Ki Yoon Kim
  • Patent number: 11064684
    Abstract: A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: July 20, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Luhan Yang, Marc Guell
  • Patent number: 11058723
    Abstract: Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: July 13, 2021
    Assignee: NantKwest, Inc.
    Inventors: Hans G. Klingemann, Laurent H. Boissel, Nathan T. Schomer
  • Patent number: 11058725
    Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: July 13, 2021
    Assignee: Obsidian Therapeutics, Inc.
    Inventors: Kutlu Goksu Elpek, Dhruv Kam Sethi, Meghan C. Langley, Tucker Read Ezell, Dexue Sun, Jennifer Leah Gori, Geetha Hanna Mylvaganam, Michelle Ols, Michelle Fleury, Celeste Richardson, James A. Storer, Vipin Suri, Shyamsundar Subramanian, Colleen Foley, Molly Reed Perkins, Jeremy Hatem Tchaicha, Scott Francis Heller
  • Patent number: 11046775
    Abstract: The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 29, 2021
    Assignee: Kite Pharma, Inc.
    Inventors: Ruben Alvarez Rodriguez, Armen Mardiros
  • Patent number: 11041863
    Abstract: A method for determining the necessity of a pre-term birth treatment is provided based on obtaining a biological sample from a subject. The biological sample is analyzed for the presence of (P33S;P168S) Frizzled4 (Fzd4) gene variation. The subject or a fetus thereof is then treated for a proclivity to pre-term birth. The Fzd4 protein itself can also be analyzed for the (P33S;P168S) Fzd4 mutation.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: June 22, 2021
    Assignee: RETINAL SOLUTIONS LLC
    Inventors: Kimberly Drenser, Michael T. Trese, Antonio Capone
  • Patent number: 11040113
    Abstract: The present invention relates to a vector which comprises a nucleic acid sequence encoding for the frataxin (FXN) gene for use in the prevention and treatment of neurological phenotype associated with Friedreich ataxia in a subject in need thereof.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: June 22, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg
    Inventors: Hélène Puccio, Françoise Piguet
  • Patent number: 11034958
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: June 15, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin A. Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
  • Patent number: 11020431
    Abstract: Provided are recombinant polynucleotides, including expression vectors encoding an alpha chain and/or a beta chain of a TCR having amino acid sequences from any of novel the AL, KQ, PP, 19305CD8, BB, KB, ST, JD, 19305DP, PB-P, PB-T, and PB 13.2 T Cell Receptors (TCRs) that are embodiments of the invention. Cells comprising the polynucleotides are provided, as are libraries of the recombinant polynucleotides and expression vectors. Methods are provided and involve administering to an individual modified human T cells that express a novel recombinant TCR. The methods are for prophylaxis and/or therapy of an individual diagnosed with, suspected of having or at risk for developing or recurrence of a cancer, wherein the cancer includes cancer cells which express NY-ESO-1 and/or its highly homologous LAGE-1 antigen.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 1, 2021
    Assignee: Health Research, Inc.
    Inventors: Adekunle Odunsi, Takemasa Tsuji, Junko Matsuzaki
  • Patent number: 11013790
    Abstract: Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immuno-isolated allogeneic cells that secrete an immunomodulator such as GM-CSF (granulocyte-macrophage colony stimulating factor) and an antigenic component such as autologous tumor cells or infectious agents. Also provided are kits and pharmaceutical compositions containing the vaccine compositions as well as methods of use thereof for therapeutic or preventative vaccination against tumors or infectious agents.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: May 25, 2021
    Assignee: MaxiVAX SA
    Inventor: Nicolas Mach
  • Patent number: 11000548
    Abstract: Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, methods of treating a cancer or tumor, methods of reducing tumor load, methods of reducing the size or growth rate of a cancer or a tumor, and methods of extending of the survival of a subject suffering from a cancer or tumor, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. Compositions and methods of use thereof may increase the efficacy of a CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm. In certain instances compositions may include additional chemotherapeutic or immunomodulatory agents.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: May 11, 2021
    Assignee: ENLIVEX THERAPEUTICS LTD
    Inventors: Shai Novik, Dror Mevorach
  • Patent number: 10993966
    Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: May 4, 2021
    Assignees: LIFE SCIENCE INSTITUTE, INC., TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Mari Dezawa, Teiji Tominaga
  • Patent number: 10986822
    Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: April 27, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer, Vera Voronina, Sean Stevens
  • Patent number: 10988542
    Abstract: The present invention relates to the field of cell immunotherapy and more particularly to a new generation of chimeric antigen receptors (CAR), allowing the control of immune cells endowed with such CARs through the interaction with small molecules. More particularly, the present invention relates to chimeric antigen receptor which comprise in at least one ectodomain a molecular switch turning the antigen binding function of the receptor from an off to on state, and vice versa. The present invention thus provides more controlled and potentially safer engineered CAR endowed immune cells, such as T-lymphocytes.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: April 27, 2021
    Assignee: CELLECTIS
    Inventors: Alexandre Juillerat, Philippe Duchateau, Laurent Poirot
  • Patent number: 10973852
    Abstract: NK cell based cancer immunotherapy, and particularly genetically modified NK92 cell-based immunotherapy is enhanced by expression CXCL12 and/or by suppression or deletion of CXCR4 in the natural killer cells to so reduce aggregation, rejection, and/or fratricide of the natural killer cells. Provided herein are genetically engineered NK (natural killer) cell comprising a recombinant nucleic acid encoding at least a portion of chemokine C—X—C motif ligand 12 (CXCL12), and a transcript for downregulation of chemokine C—X—C motif receptor 4 (CXCR4).
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: April 13, 2021
    Assignee: NantCell, Inc.
    Inventors: Patrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi
  • Patent number: 10973894
    Abstract: Disclosed are methods of isolating T cells having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in the nucleic acid of a cancer cell of a patient, each gene containing a cancer-specific mutation that encodes a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: April 13, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Eric Tran, Yong-Chen Lu, Paul Robbins, Steven A. Rosenberg
  • Patent number: 10975148
    Abstract: Disclosed is a chimeric antigen receptor comprising an antigen binding domain; a hinge region; a transmembrane domain; a costimulatory domain; and a cytoplasmic signaling domain.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 13, 2021
    Assignee: CELLABMED INC.
    Inventor: Seogkyoung Kong
  • Patent number: 10967013
    Abstract: The present invention provides an isolated lactic acid bacterium, Lactobacillus plantarum subsp. plantarum PS128 deposited under DSMZ Accession No. DSM 28632, for prophylaxis or treatment of a stress-induced disorder. The present invention further provides a composition for prophylaxis or treatment of a stress-induced disorder that comprises Lactobacillus plantarum subsp. plantarum PS128. Moreover, the present invention provides a method for prophylaxis or treatment of a stress-induced disorder in a subject that comprises a step of administering an effective amount of Lactobacillus plantarum subsp. plantarum PS128 to the subject.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: April 6, 2021
    Assignee: National Yang-Ming University
    Inventors: Ying-Chieh Tsai, Wei-Hsien Liu, Yi-Chen Juan, Chien-Chen Wu
  • Patent number: 10961312
    Abstract: CAR cells targeting FLT3 relevant antigens are described as a new method of cancer treatment. It is proposed that FLT3 CAR cells are safe and effective in patients and can be used to treat human tumors and cancer.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: March 30, 2021
    Assignee: CYTOIMMUNE THERAPEUTICS, INC.
    Inventors: Jianhua Yu, Michael Caligiuri, Steven Devine
  • Patent number: 10961509
    Abstract: In some aspects the present invention relates to engineered endothelial cells, such as E40RF1+ ETV2+ engineered endothelial cells. In other aspects the present invention relates to methods of making such engineered endothelial cells, and methods of using such engineered endothelial cells, for example in co-culture applications.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: March 30, 2021
    Inventors: Daniel Joseph Nolan, Paul William Finnegan, Michael Daniel Ginsberg, Claude Geoffrey Davis
  • Patent number: 10946066
    Abstract: A method of enhancing or initiating regeneration of an organ in a subject in need thereof comprising the administration of endothelial cells specific to said organ, or inductive endothelial cells specific to said organ, into the area of the body in which organ regeneration is desired in said subject.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: March 16, 2021
    Assignee: CORNELL UNIVERSITY
    Inventors: Shahin Rafii, Bi-Sen Ding, Sina Y. Rabbany
  • Patent number: 10927160
    Abstract: Disclosed are invariant natural killer T (iNKT) cells engineered using hematopoietic stem and progenitor cells (HSPCs) and methods of making and using thereof. Specifically, the engineered cells iNKT are genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule. Further disclosed are iNKT TCR nucleotide sequences and codon optimized sequences for expression.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: February 23, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Lili Yang, Drake J. Smith
  • Patent number: 10925263
    Abstract: A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: February 23, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Luhan Yang, Marc Guell
  • Patent number: 10919950
    Abstract: The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: February 16, 2021
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, Adam Johnson
  • Patent number: 10920195
    Abstract: The invention provides in certain embodiments, a method of generating a re-programmed differentiated epithelial cell comprising (a) contacting a non-stem somatic cell obtained from a subject with an effective amount of a de-differentiation agent to form a de-differentiated cell, and (b) transfecting the de-differentiated cell with an expression cassette comprising a promoter operably linked to a nucleic acid encoding a conversion agent to form a re-programmed differentiated cell. The invention also provides in certain embodiments, a method of generating a re-programmed differentiated epithelial cell comprising (a) contacting a non-stem somatic cell obtained from a subject with an effective amount of a de-differentiation agent to form a de-differentiated cell, and (b) contacting the de-differentiated cell with a conversion agent to form a re-programmed differentiated cell.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: February 16, 2021
    Assignee: University of Iowa Research Foundation
    Inventors: Brad A. Amendt, Thad Sharp
  • Patent number: 10906970
    Abstract: The present invention relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 2, 2021
    Assignee: Erasmus University Medical Centre
    Inventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
  • Patent number: 10900042
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: January 26, 2021
    Assignee: The United States of Americans, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10899818
    Abstract: An immunoresponsive cell, such as a T-cell expressing (i) a second generation chimeric antigen receptor comprising: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a binding element that specifically interacts with a first epitope on a target antigen; and (ii) a chimeric costimulatory receptor comprising (e) a co-stimulatory signalling region which is different to that of (b); (f) a transmembrane domain; and g) a binding element that specifically interacts with a second epitope on a target antigen. This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: January 26, 2021
    Assignee: King's College London
    Inventors: John Maher, Daniela Yordanova Achkova, Lynsey May Whilding, Benjamin Owen Draper
  • Patent number: 10888526
    Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: January 12, 2021
    Assignee: GLORIANA THERAPEUTICS SARL
    Inventors: Philip Kusk, Lars Ulrik Wahlberg
  • Patent number: 10889845
    Abstract: The present invention relates to a cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in improvement of pharmacokinetic properties, i.e. by attaching PEG chains to proteins. The present invention also relates to methods for producing the antibodies and compositions comprising the antibodies, and their uses.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: January 12, 2021
    Assignees: UNIVERSITY OF COPENHAGEN, DANMARKS TEKNISKE UNIVERSITET
    Inventors: Shamim Herbert Rahman, Carsten Behrens, Malene Bech Vester-Christensen, Henrik Clausen, Zhang Yang, Adnan Fevzi Halim, Eric Bennett
  • Patent number: 10888608
    Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: January 12, 2021
    Assignee: Bellicum Pharmaceuticals, Inc.
    Inventors: David Spencer, Aaron Edward Foster, Kevin Slawin
  • Patent number: 10881611
    Abstract: The present invention relates to RANKL+ cellular vesicles isolated from osteoblastic lineage cells, optionally immortalised, their use for the therapeutic treatment of bone pathologies and for diagnostic purposes, and processes for the production of said vesicles.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: January 5, 2021
    Assignee: Fondazione Città Della Speranza—Onlus
    Inventors: Maurizio Muraca, Alfredo Cappariello, Anna Maria Teti
  • Patent number: 10874693
    Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: December 29, 2020
    Assignee: Cellectis
    Inventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
  • Patent number: 10876123
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: December 29, 2020
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10875919
    Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent cancer.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: December 29, 2020
    Assignee: ALECTOR LLC
    Inventor: Arnon Rosenthal
  • Patent number: 10869911
    Abstract: The present invention provides a chimeric protein which comprises a multi-spanning transmembrane protein fused to a FAS endodomain, wherein the multi-spanning transmembrane protein binds an extracellular ligand, leading to activation of the FAS endodomain. The chimeric protein is useful as a suicide gene. The invention also provides a cell, such as a T cell comprising such a chimeric protein, which is useful in adoptive T cell immunotherapy approaches.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: December 22, 2020
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Brian Philip